| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA4644101
Max Phase: Preclinical
Molecular Formula: C23H30N2O4
Molecular Weight: 398.50
Molecule Type: Unknown
Associated Items:
Representations
Canonical SMILES: COc1ccc(OCC2c3ccc(OC)cc3CC(=O)N2CCCN(C)C)cc1
Standard InChI: InChI=1S/C23H30N2O4/c1-24(2)12-5-13-25-22(16-29-19-8-6-18(27-3)7-9-19)21-11-10-20(28-4)14-17(21)15-23(25)26/h6-11,14,22H,5,12-13,15-16H2,1-4H3
Standard InChI Key: MMZKPVCTUYKFKI-UHFFFAOYSA-N
Associated Targets(non-human)
Glutamate NMDA receptor; Grin1/Grin2c 1127 Activities
Ionotropic glutamate receptor NMDA 1/2D 870 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Glutamate NMDA receptor; Grin1/Grin2a 798 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Glutamate NMDA receptor; Grin1/Grin2b 1028 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 398.50 | Molecular Weight (Monoisotopic): 398.2206 | AlogP: 3.16 | #Rotatable Bonds: 9 |
| Polar Surface Area: 51.24 | Molecular Species: BASE | HBA: 5 | HBD: 0 |
| #RO5 Violations: 0 | HBA (Lipinski): 6 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: | CX Basic pKa: 9.30 | CX LogP: 2.47 | CX LogD: 0.58 |
| Aromatic Rings: 2 | Heavy Atoms: 29 | QED Weighted: 0.65 | Np Likeness Score: -0.43 |
References
| 1. Epplin MP, Mohan A, Harris LD, Zhu Z, Strong KL, Bacsa J, Le P, Menaldino DS, Traynelis SF, Liotta DC.. (2020) Discovery of Dihydropyrrolo[1,2-a]pyrazin-3(4H)-one-Based Second-Generation GluN2C- and GluN2D-Selective Positive Allosteric Modulators (PAMs) of the N-Methyl-d-Aspartate (NMDA) Receptor., 63 (14): [PMID:32538088] [10.1021/acs.jmedchem.9b01733] |
Source
Source(1):